跳至主要内容

CRO employee turnover rate falls as industry matures, survey finds


Over the last three years US turnover in clinical monitoring has dropped from 29.4% to 16.4% and globally overall company turnover has dropped from 27.2% to 14.2% on average, according to the 16th annual CRO Industry Global Compensation and Turnover Survey.

The survey from HR+Survey Solutions found that turnover globally was the highest in Switzerland, New Zealand and Hong Kong.
Study author Judy Canavan told Outsourcing-Pharma.com, “The CRO industry is a niche industry so it is easy for a couple of companies to drive high turnover numbers in a specific country. The industry is expanding rapidly... This growth creates a demand for talent which drives turnover.”
She noted that the falling turnover rates in the past couple of years may be a sign that the industry is maturing. The relatively high turnover rate that remains, she added, seems to be the product of a number of factors, including:
  • Home-based positions that create two issues (1) changing jobs is as simple as getting a new computer, VPN and password (2) it is harder to create a cohesive team when employees do not see each other every day;
  • Travel – many of these positions require extensive travel, employees may find a job that has less travel or travel to a more desirable location;
  • The demands placed in some of these positions are high – in addition to extensive travel there can be tight deadlines, tight budgets and high performance expectations; and
  • CV building – if there is an opportunity to enhance one’s resume, then it may be worth changing jobs for future career growth. 
In terms of retaining talent, Canavan told us that annual corporate bonuses are probably not “the answer for all positions,” and there “needs to be more customization of incentive comp and rewards to meet the needs of individual areas of the company.”
Smaller CROs may have to do more to incentivize employees to stay at the companies, the survey said. It also found that non-management employees of large and small companies are paid comparable salaries, though smaller companies are less likely to pay annual incentives than larger companies.
Nearly 88 percent of director level positions at the larger US CROs received annual incentives versus 65 percent at smaller companies, the survey found.
The CRO with 200 employees is competing for talent against CROs with 10,000 employees. Smaller companies should be using variable pay to help them compete against larger companies for top talent while controlling fixed costs,” said Canavan.
Other findings from the survey include:
  • Average salary levels in the survey only increased by 1% for non-management positions;
  • CRO pay for executives is more heavily weighted toward salaries than in general industry; and
  • On average, the bonus for smaller companies is almost 25 percent less than that for larger companies; however, the size of the awards for smaller companies that pay bonuses tends to be similar to that of the larger companies.

评论

此博客中的热门博文

What is preclinical testing?

In the process of  preclinical testing  of a compound or biological agent into a drug, the compound involved must go through the testing phase. First, we need to identify potential targets that can treat the disease. Then, a variety of compounds or preparations are screened out. Any compound that has shown potential as a drug for the treatment of this disease needs to be tested for toxicity before clinical testing to reduce the possibility of injury. preclinical testing What is the basis of preclinical testing? According to US Food and Drug Administration (FDA) regulations, a series of tests are required before a new drug is approved for use. In the first stage, basic research determines a hypothetical target for the treatment of a certain disease, and then screens small molecules or biological compounds to discover any substance with the potential to treat the disease. Then, a  preclinical research  phase followed, before which, as described above, the potential toxicity of the compou

Inventory of the three major in vitro pharmacokinetic research methods

  The metabolic properties of a compound are an essential factor in whether or not it can be used as a drug in the clinical setting, so pharmacokinetic studies of newly synthesized compounds are required in drug development. In vitro incubation with liver microsomes, recombinant CYP450 enzyme lines, and in vitro incubation with hepatocytes are some of the more common in vitro drug metabolism methods. 1. In vitro incubation method with liver microsomes The metabolic stability and metabolic phenotypes of candidate compounds in different species of liver microsomes are good predictors of the metabolic properties of compounds in vivo. They are practical tools for evaluating candidate compounds in the pre-development phase of drug development. Liver microsomes include rat liver microsomes, human liver microsomes, canine liver microsomes, monkey liver microsomes, and mouse liver microsomes. In in vitro incubation of the liver, microsomes are the "gold standard" for in vitro d

Novel Parkinson’s Therapies Possible with New Mouse Model

Parkinson's disease (PD) is a neurodegenerative disorder that is marked by the accumulation of the protein, α-synuclein (αS), into clumps known as Lewy bodies, which diminish neural health. Now, researchers from Brigham and Women's Hospital (BWH) report the development of a mouse model to induce PD-like αS aggregation, leading to resting tremor and abnormal movement control. The mouse responds to L-DOPA, similarly to patients with PD. The team's study (“Abrogating Native α-Synuclein Tetramers in Mice Causes a L-DOPA-Responsive Motor Syndrome Closely Resembling Parkinson’s Disease”) on the use of this transgenic mouse model appears in  Neuron . “α-Synuclein (αS) regulates vesicle exocytosis but forms insoluble deposits in PD. Developing disease-modifying therapies requires animal models that reproduce cardinal features of PD. We recently described a previously unrecognized physiological form of αS, α-helical tetramers, and showed that familial PD-causing missense mutati